Qualitek Labs [QLL] vs Krsnaa Diagnostics [KRSNAA] Detailed Stock Comparison
Qualitek Labs
BSE
Loading...
Krsnaa Diagnostics
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Qualitek Labs wins in 5 metrics, Krsnaa Diagnostics wins in 11 metrics, with 0 ties. Krsnaa Diagnostics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Qualitek Labs | Krsnaa Diagnostics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 45.40 | 33.93 | Krsnaa Diagnostics |
| Price-to-Book Ratio | 3.29 | 3.02 | Krsnaa Diagnostics |
| Debt-to-Equity Ratio | 37.74 | 23.06 | Krsnaa Diagnostics |
| PEG Ratio | N/A | 2.35 | N/A |
| EV/EBITDA | 22.03 | 13.74 | Krsnaa Diagnostics |
| Profit Margin (TTM) | 8.97% | 10.84% | Krsnaa Diagnostics |
| Operating Margin (TTM) | 20.77% | 15.42% | Qualitek Labs |
| EBITDA Margin (TTM) | 20.77% | 15.42% | Qualitek Labs |
| Return on Equity | 12.27% | 8.79% | Qualitek Labs |
| Return on Assets (TTM) | 7.19% | 6.06% | Qualitek Labs |
| Free Cash Flow (TTM) | $-48.03M | $-393.00M | Qualitek Labs |
| Dividend Yield | N/A | 0.36% | N/A |
| 1-Year Return | -1.65% | 11.80% | Krsnaa Diagnostics |
| Price-to-Sales Ratio (TTM) | 4.56 | 3.62 | Krsnaa Diagnostics |
| Enterprise Value | $2.95B | $28.04B | Krsnaa Diagnostics |
| EV/Revenue Ratio | 4.20 | 3.79 | Krsnaa Diagnostics |
| Gross Profit Margin (TTM) | N/A | 67.46% | N/A |
| Revenue per Share (TTM) | $79 | $229 | Krsnaa Diagnostics |
| Earnings per Share (Diluted) | $7.07 | $24.34 | Krsnaa Diagnostics |
| Beta (Stock Volatility) | N/A | -0.15 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Qualitek Labs vs Krsnaa Diagnostics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Qualitek Labs | 3.87% | 3.21% | 4.58% | 2.40% | 36.93% | -10.04% |
| Krsnaa Diagnostics | -0.04% | -2.03% | -5.30% | 25.27% | 10.14% | -11.16% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Qualitek Labs | -1.65% | 113.18% | 113.18% | 113.18% | 113.18% | 113.18% |
| Krsnaa Diagnostics | 11.80% | 69.40% | -12.70% | -12.70% | -12.70% | -12.70% |
Performance & Financial Health Analysis: Qualitek Labs vs Krsnaa Diagnostics
| Metric | QLL | KRSNAA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.20B | ₹26.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 7,760 | 73,619 |
| 90 Day Avg. Volume | 7,493 | 113,966 |
| Last Close | ₹330.00 | ₹809.15 |
| 52 Week Range | ₹215.05 - ₹375.00 | ₹625.75 - ₹1,044.00 |
| % from 52W High | -12.00% | -22.50% |
| All-Time High | ₹375.00 (Dec 23, 2024) | ₹1,099.70 (Aug 16, 2021) |
| % from All-Time High | -12.00% | -26.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.13% |
| Quarterly Earnings Growth | N/A | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.11% |
| Operating Margin (TTM) | 0.21% | 0.15% |
| Return on Equity (TTM) | 0.12% | 0.09% |
| Debt to Equity (MRQ) | 37.74 | 23.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹97.54 | ₹273.22 |
| Cash per Share (MRQ) | ₹1.99 | ₹21.18 |
| Operating Cash Flow (TTM) | ₹53.16M | ₹2.45M |
| Levered Free Cash Flow (TTM) | ₹76.84M | ₹776.08M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.36% |
| Last 12-Month Dividend | N/A | ₹2.50 |
Valuation & Enterprise Metrics Analysis: Qualitek Labs vs Krsnaa Diagnostics
| Metric | QLL | KRSNAA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 45.40 | 33.93 |
| Forward P/E | N/A | 20.48 |
| PEG Ratio | N/A | 2.35 |
| Price to Sales (TTM) | 4.56 | 3.62 |
| Price to Book (MRQ) | 3.29 | 3.02 |
| Market Capitalization | ||
| Market Capitalization | ₹3.20B | ₹26.80B |
| Enterprise Value | ₹2.95B | ₹28.04B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.20 | 3.79 |
| Enterprise to EBITDA | 22.03 | 13.74 |
| Risk & Other Metrics | ||
| Beta | N/A | -0.15 |
| Book Value per Share (MRQ) | ₹97.54 | ₹273.22 |
Financial Statements Comparison: Qualitek Labs vs Krsnaa Diagnostics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QLL | KRSNAA |
|---|---|---|
| Revenue/Sales | N/A | ₹1.86B |
| Cost of Goods Sold | N/A | ₹589.52M |
| Gross Profit | N/A | ₹1.27B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | ₹310.28M |
| EBITDA | N/A | ₹573.71M |
| Pre-Tax Income | N/A | ₹286.03M |
| Income Tax | N/A | ₹79.27M |
| Net Income (Profit) | N/A | ₹206.76M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QLL | KRSNAA |
|---|---|---|
| Cash & Equivalents | ₹51.74M | ₹38.45M |
| Total Current Assets | ₹426.08M | ₹4.14B |
| Total Current Liabilities | ₹325.84M | ₹3.05B |
| Long-Term Debt | ₹308.61M | ₹471.56M |
| Total Shareholders Equity | ₹927.82M | ₹8.83B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹589.98M | ₹6.67B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QLL | KRSNAA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QLL | KRSNAA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 7,760 | 73,619 |
| Average Daily Volume (90 Day) | 7,493 | 113,966 |
| Shares Outstanding | 9.98M | 32.29M |
| Float Shares | 711,777 | 17.39M |
| % Held by Insiders | 0.69% | 0.44% |
| % Held by Institutions | 0.00% | 0.15% |
Dividend Analysis & Yield Comparison: Qualitek Labs vs Krsnaa Diagnostics
| Metric | QLL | KRSNAA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹2.50 |
| Last 12-Month Dividend Yield | N/A | 0.36% |
| 3-Year Avg Annual Dividend | N/A | ₹2.58 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | ₹7.75 |
| Ex-Dividend Date | N/A | Sep 13, 2024 |